Ironwood Pharmaceuticals (IRWD) EPS (Weighted Average and Diluted) (2010 - 2026)

Ironwood Pharmaceuticals has disclosed EPS (Weighted Average and Diluted) across 13 years of filings, most recently posting $0.24 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.24, up 204.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.6 (up 385.71% YoY), and the FY2025 annual result was $0.15, up 1400.0% from the prior year.
• EPS (Weighted Average and Diluted) came in at $0.24 for Q1 2026 at Ironwood Pharmaceuticals, up from -$0.01 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.28 in Q3 2022 to a low of -$6.84 in Q2 2023.
• The 5-year median for EPS (Weighted Average and Diluted) is $0.09 (2023), against an average of -$0.3.
• Across the five-year window, EPS (Weighted Average and Diluted) sank 3357.14% in 2023 and jumped 1500.0% in 2025, its largest moves.
• Ironwood Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.27 in 2022, then sank by 103.7% to -$0.01 in 2023, then soared by 200.0% to $0.01 in 2024, then slumped by 200.0% to -$0.01 in 2025, then surged by 2500.0% to $0.24 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.24 (Q1 2026), -$0.01 (Q4 2025), and $0.23 (Q3 2025), per Business Quant data.